Literature DB >> 7478604

Functional domains of the t(8;21) fusion protein, AML-1/ETO.

N Lenny1, S Meyers, S W Hiebert.   

Abstract

The AML-1/ETO fusion protein is created by the (8;21) translocation, the second most frequent chromosomal abnormality associated with acute myeloid leukemia. In the fusion protein the AML-1 runt homology domain, which is responsible for DNA binding and CBF beta interaction, is linked to ETO, a gene of unknown function. The primary sequences of the runt homology domain indicates no known DNA binding motifs, but is predicted to contain six beta-strands, two alpha-helices and a nucleotide binding motif. Mutagenesis of AML-1/ETO was performed to delimit the functional domains of the chimeric protein. Most mutations in the runt homology domain that resulted in reduced CBF beta binding also inhibited DNA binding, indicating that the DNA and CBF beta binding sequences are tightly linked. However, these activities were separated by a point mutation of residue 144, within the putative ATP binding motif, which nearly eliminated DNA binding, but did not affect CBF beta binding. Random mutagenesis identified the hydrophobic face of the amphipathic fifth beta-strand, adjacent to the putative ATP binding motif, as critical for both DNA and CBF beta binding. C-terminal deletion mutants of AML-1/ETO indicated that ETO sequences are essential for interference with AML-1B-mediated transcriptional activation, and that residue 540 defines the C-terminal boundary of a potential repression domain. Thus, these mutational analyses define the regions of AML-1/ETO which regulate its function and that may be important in promoting leukemia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478604

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

1.  The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription.

Authors:  S W Hiebert; W Sun; J N Davis; T Golub; S Shurtleff; A Buijs; J R Downing; G Grosveld; M F Roussell; D G Gilliland; N Lenny; S Meyers
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

2.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

3.  The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein.

Authors:  B Lutterbach; D Sun; J Schuetz; S W Hiebert
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

4.  Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1.

Authors:  M S Petrovick; S W Hiebert; A D Friedman; C J Hetherington; D G Tenen; D E Zhang
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

5.  CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter.

Authors:  D E Zhang; C J Hetherington; S Meyers; K L Rhoades; C J Larson; H M Chen; S W Hiebert; D G Tenen
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

Review 6.  Transcriptional regulation during myelopoiesis.

Authors:  N Lenny; J J Westendorf; S W Hiebert
Journal:  Mol Biol Rep       Date:  1997-08       Impact factor: 2.316

7.  Groucho-dependent and -independent repression activities of Runt domain proteins.

Authors:  B D Aronson; A L Fisher; K Blechman; M Caudy; J P Gergen
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

8.  Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis.

Authors:  K L Rhoades; C J Hetherington; J D Rowley; S W Hiebert; G Nucifora; D G Tenen; D E Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

9.  ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.

Authors:  J Wang; T Hoshino; R L Redner; S Kajigaya; J M Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

10.  The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.

Authors:  Luke F Peterson; Ming Yan; Dong-Er Zhang
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.